drugset
drugset / Trial / NCT04272034

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors

NCT04272034 ↗

Phase 1 Terminated 105 enrolled Incyte Corporation
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics of INCB099318 in select solid tumors.

Timeline

Start
2021-03-26
Primary completion
2024-08-16
Completion
2024-08-16

Outcome

Outcome not reported

Stopped (Enrollment): “A business decision was made to discontinue further enrollment. There were no safety concerns that contributed to this decision.”

Drugs

EvaluationDrugModalityDoseRoute
Subject INCB099318 Unknown 20 mg Oral
Subject INCB099318 Unknown 100 mg Oral

Indications

anal carcinoma cervical cancer cutaneous neuroendocrine carcinoma esophageal squamous cell carcinoma mesothelioma nasopharyngeal carcinoma sarcomatoid renal cell carcinoma skin basal cell carcinoma skin squamous cell carcinoma small cell lung carcinoma squamous cell carcinoma of penis urothelial carcinoma